Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
STX107
print preview
bookmark
share with colleague
General Information
Company
Merck & Co. Inc.
Description
Metabotropic glutamate receptor subtype 5 (mGluR5) antagonist
Molecular Target
Metabotropic glutamate receptor subtype 5 (mGluR5) (GRM5)
Mechanism of Action
Metabotropic glutamate receptor subtype 5 (mGluR5) antagonist
Latest Stage of Development
Phase II
Indication
Fragile X syndrome
Partner
Seaside Therapeutics Inc.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy